GWM
KROS icon

Geneos Wealth Management’s Keros Therapeutics KROS Stock Holding History

Geneos Wealth Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-83
Closed -$1.11K – 2858
2025
Q2 		$1.11K Buy
+83
New +$1.12K ﹤0.01% 2957

Other funds holding KROS

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Geneos Wealth Management's KROS Position: Q3 2025 in Review

Geneos Wealth Management sold out of Keros Therapeutics (KROS) in Q3 2025, closing a stake of 83 shares — an estimated $1.11K sold.

Geneos Wealth Management first reported a position in KROS in Q2 2025 and held it in 1 quarter. The position peaked at $1.11K in Q2 2025. 155 funds tracked by Wall St. Rank hold KROS as of Q3 2025.

  • Geneos Wealth Management reported no remaining Keros Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Geneos Wealth Management sold 83 Keros Therapeutics shares in Q3 2025, an estimated $1.11K.
  • Geneos Wealth Management first reported a position in Keros Therapeutics in Q2 2025 and held it in 1 quarter.
  • Geneos Wealth Management's Keros Therapeutics position peaked at $1.11K in Q2 2025.
  • 155 funds tracked by Wall St. Rank held Keros Therapeutics as of Q3 2025.

Based on Geneos Wealth Management's 13F filing for Q3 2025, filed 22 Oct 2025.